Announcement on Resignation of Senior Management Member
Filed with SSE · · 1 page · Chinese
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on Holding Subsidiary Second Pharma Co., Ltd. Passing GMP Compliance Inspection
- Announcement on the Receipt of the Drug Supplement Approval Notice for Potassium Chloride Injection by Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd.
- Announcement on Obtaining Drug Registration Certificate for Some Products by Wholly-owned Subsidiary
- Notice on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on Convening the 2025 Semi-annual Performance Briefing
Later from China Resources Double-Crane Pharmaceutical
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on the Wholly-Owned Subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. Receiving the Approval Notice for the Supplemental Drug Application of Peritoneal Dialysis Solution (Lactic Acid) Series
- Announcement on Wholly-Owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Tirofiban Hydrochloride and Sodium Chloride Injection
- Announcement on Wholly-owned Subsidiary China Resources Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. Obtaining the Drug Registration Certificate for Bosentan Dispersible Tablets
- Announcement on Convening the Q3 2025 Performance Briefing
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical